ASP3082 for neoplasm metastasis

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 19 Mar 2026: Trial registered, NCT07483983
  2. 25 Mar 2026: Trial started, NCT07483983

The trials

NCT07483983: Study Investigating ASP3082 in Patients With Metastatic/Locally Advanced Non-small-cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), With Biomarker Analysis to Characterize Response/Resistance

State
Under way
Phase
Phase 2
People
60 planned
Started
25 Mar 2026
Primary completion
Sep 2027
Arms
Cohort NSCLC, Cohort PDAC
Results
None posted
  1. 19 Mar 2026: Trial registered
  2. 25 Mar 2026: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.